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Abstract
Background: The authors report a case of a rare complication that occurred after botulinum toxin injection to the
extraocular muscle, which was easily overlooked and successfully corrected by surgery.
Case presentation: A 34-year-old female patient visited our clinic for diplopia and ocular motility disorder after
removal of an epidermoid tumor of the brain. At her initial visit, her best-corrected visual acuity (BCVA) was 20/20
for both eyes. An alternate cover test showed 45 prism-diopter esotropia and 3 prism-diopter hypertropia in the
right eye. Following 6 months of observation, the deviation of the strabismus did not improve, and botulinum toxin
was injected into the right medial rectus (RMR). After 6 days, she visited our clinic with decreased visual acuity of
her right eye. The BCVA was found to be 20/50 for her right eye. Funduscopic examination presented a retinal tear
inferonasal to the optic disc with preretinal hemorrhage. Subretinal fluid nasal to the fovea was seen on optical
coherence tomography (OCT). Barrier laser photocoagulation was done around the retinal tear; however, her visual
acuity continued to decrease, and vitreous hemorrhage and subretinal fluid at the lesion did not improve. In
addition, a newly developed epiretinal membrane was seen on OCT. An alternate cover test presented 30 prism-diopter
right esotropia. 19 weeks after RMR botulinum toxin injection, she received pars plana vitrectomy, membranectomy,
endolaser barrier photocoagulation, and intravitreal bevacizumab (Avastin®) injection. After 4 months, her visual acuity
improved to 20/20, and only 4 prism-diopter of right hypertropia and 3 prism-diopter of exotropia were noted. Vitreous
opacity and the epiretinal membrane were completely removed, as confirmed by funduscopic and examination.
Conclusions: Sudden loss of vision after injection of botulinum toxin into the extraocular muscle may suggest a serious
complication, and a prompt, thorough ophthalmic examination should be performed. If improvements are not observed,
rapid surgical intervention is recommended to prevent additional complications.
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Background
Botulinum toxin is a widely used drug for the treatment of
various ophthalmologic disease. In addition to cosmetic
uses, botulinum toxin injection can be useful in the treat-
ment of a variety of ocular muscle disorders, including
strabismus [1], blepharospasm [2], upper eye lid retraction
[3], entropion [4] and facial paralysis [5]. Botulinum toxin
acts by blocking the release of acetylcholine from the syn-
aptic cleft of the neuromuscular junction, thereby leading
to chemical denervation of the muscle and reduced
muscle activity. Further, during strabismus surgery, botu-
linum toxin acts to weaken the antagonist muscle and
correct the deviation of the eyeball [6].
Rhegmatogenous retinal detachment (RRD) occurs
when liquefied vitreous enters a previously created retinal
hole or tear and causes detachment between the neuro-
sensory retina and the retinal pigment epithelium (RPE).
The detached retina should be reattached promptly to
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avoid severe vision loss. Surgical interventions to treat RRD
include pars plana vitrectomy (PPV), scleral buckle (SB),
PPV with a SB, and pneumatic retinopexy [7]. Proliferative
vitreoretinopathy (PVR), a major complication of chronic
RRD, is a common cause for the failure of surgical repairs.
The prognosis of patients with PVR is poor because many
cytokines derived from the vitreous trigger proliferation
and migration of the RPE, leading to epithelial-
mesenchymal transition and formation of a fibrous mem-
brane that aggravates retinal detachment [8–11].
Although complications, including edema, bruising,
pain, and headache, can occur as a result of botulinum
toxin injection, most are self-limited and only last a
short period [12]. However, severe complications, such
as perforation of the globe, may develop inadvertently as
a result.
The authors report a case of a young female who was
diagnosed with RRD with PVR 6 days after botulinum
toxin injection into the extraocular muscle. The patient
was healed completely through surgical intervention.
Case presentation
A 34-year-old female patient, with a history of laser epi-
thelial keratomileusis, visited our clinic for diplopia and
ocular motility disorder after removal of an epidermoid
tumor at the prepontine cistern of the brain because of
right 6th nerve palsy. At her initial visit, her best-
corrected visual acuity (BCVA) was 20/20 for both eyes.
An alternate cover test showed 45 prism-diopter esotropia
and 3 prism-diopter hypertropia in the right eye. The
patient was diagnosed with paralytic strabismus, and we
planned to observe her for about two to three months to
check changes in the amount of deviation. However, as
the patient failed to visit outpatient clinic since then, fur-
ther follow-up was unavailable. She revisited at 6 months
after the development of her first symptom. Following
6 months of observation, angle of deviation did not
improve, and 0.2 cm3 of botulinum toxin (2.5 inter-
national units) were injected into the right medial rectus
(RMR). After 6 days, she visited our clinic complaining of
decreased visual acuity of her right eye. The BCVA and in-
traocular pressure (IOP) for her right eye were found to
be 20/50 and 15 mmHg, respectively. Based on fundu-
scopic examination, a retinal hole was located 4 DD (disc
diameter) inferonasally from the optic disc, and both pre-
retinal and vitreous hemorrhages were present in front of
the lesion (Fig. 1a). Optical coherence tomography (OCT)
examination revealed subretinal fluid nasal to the fovea,
but central fovea was attached (Fig. 1b, c). The patient was
diagnosed with RRD with macula off, but because of small
subretinal fluid and tiny retinal break, we decided to ob-
serve it first. Barrier laser photocoagulation around the
retinal hole was performed (Fig. 1d). However, the pa-
tient’s visual acuity continued to decrease without im-
provement of vitreous hemorrhage, and at 12 weeks after
botulinum toxin injection, a newly developed tractional
membrane from macula to inferonasal periphery was
noted, suggesting PVR development (Fig. 2a, b). An alter-
nate cover test presented 30 prism-diopter right esotropia.
19 weeks following RMR botulinum toxin injection, she
received PPV, membranectomy, peeling of the internal
limiting membrane, and endolaser barrier photocoagula-
tion. After 4 months, her visual acuity improved to 20/20,
and only 4 prism-diopter of right hypertropia and 3
Fig. 1 6 days after botulinum toxin injection to the right medial rectus muscle. a A wide-field color fundus photo shows a retinal tear inferonasal
to the optic disc with preretinal hemorrhage nearly blocking the site. b, c SD-OCT B-scan images reveal subretinal fluid nasal to the fovea; however, the
central fovea was intact. d One week after application of barrier laser photocoagulation around the retinal tear, the preretinal hemorrhage remained inferior
to the optic disc
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prism-diopter of exotropia were noted. Vitreous opacity
and the epiretinal membrane were completely removed
(Fig. 2c, d). Serious adverse complications, including en-
dophthalmitis, retinal re-detachment, and increased IOP,
were not observed.
Discussion and conclusions
Although botulinum toxin is a relatively safe medication
with few complications, some unexpected, adverse
events can occur after injection. And a majority of those
adverse events occurred immediately after or during
procedure [13–15]. Liu M et al. reported a case in which
the botulinum toxin was improperly injected into the
vitreous cavity of a patient receiving treatment to the
right medial rectus, resulting in increased IOP, decreased
visual acuity, and retinal detachment [13]. The patient
received topical and oral antibiotic treatment and spon-
taneously recovered without any further complications.
In our case, however, the retinal detachment did not
improve spontaneously, and the development of PVR
necessitated surgical intervention.
Most studies have found intraocular botulinum toxin
injection to be safe. Kutlut S et al. reported no difference
in the retinal function of rabbit eyes that received intra-
ocular botulinum toxin injection versus controls that
received only intraocular saline injection, as confirmed
by visual evoked potential and electroretinogram (ERG)
test [16]. Likewise, Gatzioufas Z et al. reported IOP im-
mediately increased after intravitreal botulinum toxin
injection in normotensive rats; however, the density of
retinal ganglion cells and immunostaining pattern of
rhodopsin and retinal glial fibrillary acidic protein
showed no difference between the group injected with
botulinum toxin and the control group injected with bal-
anced salt solution [17]. Pehere N et al. reported a case
of unintentional injection of botulinum toxin into the
eyeball that recovered without any complications other
than a slight increase in intraocular pressure [18]. In our
case, small amount of botulinum toxin, which might
have been injected into the eyeball, did not affect the
final visual acuity or intraocular pressure. To sum up,
these reports suggest that, in most cases, botulinum
toxin injected inadvertently into the eyeball does not
appear to be toxic. However, periorbital botulinum toxin
injection can cause mydriasis of the pupil, resulting in
acute angle closure attack [19]. Further, spreading of the
botulinum toxin to adjacent muscles, including the
levator and inferior rectus muscles, can lead to the de-
velopment of ptosis or vertical strabismus [20]. To solve
these problems, peri- or retrobulbar anesthesia should
be considered when electromyography (EMG) is not
available [14]. By stretching the extraocular muscle
slightly to make a free space between the extraocular
muscle and the ocular surface [21], unintentional perfor-
ation of the globe can be prevented.
Although the procedure was done under EMG guidance,
the patient underwent scleral perforation. Her axial length
which was taken before PPV was 25.15 mm, which sug-
gests that the patient might have had moderate myopia.
Myopia is known to be a risk factor for scleral perforation
in various surgical interventions, including strabismus sur-
gery [22] and retro- or peribulbar anesthesia [23]. There-
fore, we concluded that the risk factor was obscured due to
past history of refractive surgery. Accordingly, when
Fig. 2 a 11 weeks after botulinum toxin injection. Note the fibrous membrane extending from the macula to the nasal mid-periphery and the
vitreous hemorrhage that remained at the inferonasal quadrant. b A SD-OCT cross-sectional image reveals a thick epiretinal membrane corresponding
to the fibrous membrane adherent to the central macula. c 18 weeks after PPV with visual acuity of 20/20. The scar change nasal to the optic disc
remained, but the overall retina was remarkably flattened. d A SD-OCT B-scan image showed the flattened retina with minimal intraretinal
cystic changes and a recovered photoreceptor layer
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planning botulinum toxin injection into extraocular
muscle, surgeon should be fully aware of patient’s refractive
error as well as history of any kind of refractive surgery, in
order to prevent inadvertent scleral perforation (Additional
file 1 and Additional file 2).
In this case, the procedure was performed under EMG
guidance, and no immediate problems were observed.
However, after 6 days, the patient visited our clinic
because of decreased visual acuity, and retinal detach-
ment with preretinal hemorrhage was present. And the
patient eventually had to undergo surgery to correct for
the anatomical abnormality. Thus, the authors suggest
that if a patient comes to the hospital presenting with a
sudden loss of vision after botulinum toxin injection, a
thorough ophthalmic examination, which includes a fun-
duscopic examination, should be performed. If improve-
ment is not observed, prompt surgical intervention must
be executed to avoid more serious complications. To
prevent such serious complications, surgeons should
thoroughly review the patient’s past history and perform
detailed examination to identify various risk factors,
such as myopia and scleral scar, when planning botu-
linum toxin injection into extraocular muscle.
In conclusion, physicians should pay close attention to
the uncommon complications that may arise during
botulinum toxin injection, and respond properly in a
suspicious situation with a variety of methods including
either medical or surgical intervention. Moreover, know-
ing the patient’s risk factors before treatment helps to
reduce such complications.
Additional files
Additional file 1: Patient Perspective. This document has been confirmed
to the patient who was the subject of this case report. (DOCX 17 kb)
Additional file 2: Timeline Picture of Our Case Report. This document is
a simple diagram that shows a patient’s visit to our hospital, a series of
tests that she had received, and healed course. (DOCX 46 kb)
Abbreviations
BCVA: Best-corrected visual acuity; DD: Disc diameter;
EMG: Electromyography; ERG: Electroretinogram; IOP: Intraocular pressure;
OCT: Optical coherence tomography; PPV: Pars plana vitrectomy;
PVR: Proliferative vitreoretinopathy; RMR: Right medial rectus; RPE: Retinal





The authors declare that they have no sources of funding.
Availability of data and materials
The datasets used and/or analysed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
Involved in Conception and design of study (DHL, JH, SHH, MK); and Writing
the article (DHL, MK); Critical revision of the article (SCL); and final approval
of the manuscript (all authors).
Ethics approval and consent to participate
Not applicable.
Consent for publication
Written informed consent was obtained from the patient.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Institute of Vision Research, Department of Ophthalmology, Severance Eye
and ENT Hospital, Yonsei University College of Medicine, Seoul, South Korea.
2Department of Ophthalmology, Gangnam Severance Hospital, Yonsei
University College of Medicine, Seoul, South Korea.
Received: 12 July 2017 Accepted: 5 December 2017
References
1. Donahue SP. Botulinum toxin treatment for esotropia. Am Orthopt J. 2013;
63:29–31.
2. Sung Y, Nam SM, Lew H. Clinical outcomes of individualized botulinum
neurotoxin type a injection techniques in patients with essential
blepharospasm. Korean J Ophthalmol. 2015;29(2):115–20.
3. Chuenkongkaew W. Botulinum toxin treatment for upper lid retraction of
dysthyroidism. J Med Assoc Thail. 2003;86(11):1051–4.
4. Deka A, Saikia SP. Botulinum toxin for lower lid entropion correction. Orbit.
2011;30(1):40–2.
5. Cooper L, Lui M, Nduka C. Botulinum toxin treatment for facial palsy: a
systematic review. J Plast Reconstr Aesthet Surg. 2017;70(6):833–41.
6. Akbari MR, Ameri A, Keshtkar Jaafari AR, Mirmohammadsadeghi A.
Botulinum toxin injection for restrictive myopathy of thyroid-associated
orbitopathy: success rate and predictive factors. J aapos. 2016;20(2):126–30.
e121
7. Haugstad M, Moosmayer S, Bragadόttir R. Primary rhegmatogenous retinal
detachment - surgical methods and anatomical outcome. Acta Ophthalmol.
2017;95(3):247–51.
8. Ciprian D. The Pathogeny of proliferative Vitireoretinopathy. Rom J
Ophthalmol. 2015;59(2):88–92.
9. Danielescu C, Zugun-Eloae F, Zlei M. Concentrations of Vitreal cytokines in
Rhegmatogenous retinal detachment. Rev Med Chir Soc Med Nat Iasi. 2016;
120(1):124–9.
10. Yang S, Li H, Li M, Wang F. Mechanisms of epithelial-mesenchymal
transition in proliferative vitreoretinopathy. Discov Med. 2015;20(110):
207–17.
11. Charteris DG. Proliferative vitreoretinopathy: pathobiology, surgical
management, and adjunctive treatment. Br J Ophthalmol. 1995;79(10):
953–60.
12. Basar E, Arici C. Use of Botulinum neurotoxin in ophthalmology. Turk J
Ophthalmol. 2016;46(6):282–90.
13. Liu M, Lee HC, Hertle RW, Ho AC. Retinal detachment from inadvertent
intraocular injection of botulinum toxin a. Am J Ophthalmol. 2004;137(1):
201–2.
14. Agrawal S, Singh V, Gupta SK, Kumar BV. Vitreous hemorrhage following
inadvertent intra-ocular injection of botulinum toxin. Oman J Ophthalmol.
2015;8(1):79–80.
15. Mohan M, Fleck BW. Globe perforation during botulinum toxin injection. Br
J Ophthalmol. 1999;83(4):503–4.
16. Kutluk S, Akar S, Topcu M, Kural G. Effect of botulinum toxin injections into
rabbit eye. Strabismus. 1999;7(4):221–6.
Lee et al. BMC Ophthalmology  (2017) 17:249 Page 4 of 5
17. Gatzioufas Z, Stupp T, Moschos MM, Kopsidas K, Charalambous P, Thanos S.
Effect of botulinum toxin a on the intraocular pressure and the retina in an
animal model. Cutan Ocul Toxicol. 2013;32(2):107–11.
18. Pehere N, Jalali S, Mathai A, Naik M, Ramesh K. Inadvertent intraocular
injection of botulinum toxin a. J Pediatr Ophthalmol Strabismus. 2011;48
Online:e1–3.
19. Zheng L, Azar D. Angle-closure glaucoma following periorbital botulinum
toxin injection. Clin Exp Ophthalmol. 2014;42(7):690–3.
20. Lennerstrand G, Nordbo OA, Tian S, Eriksson-Derouet B, Ali T. Treatment of
strabismus and nystagmus with botulinum toxin type A. An evaluation of
effects and complications. Acta Ophthalmol Scand. 1998;76(1):27.
21. Wan XM, Chu RX, Gong HQ. Minimally invasive botulinum toxin type a
injection from the ocular surface to extraocular muscles. Int J Ophthalmol.
2011;4(2):179–81.
22. Park K, Hong S, Chung W, Kim SS, Byeon SH, Seong GJ, Lee JB, Han SH.
Inadvertent scleral perforation after strabismus surgery: incidence and
association with refractive error. Can J Ophthalmol. 2008;43(6):669–72.
23. Schrader WF, Schargus M, Schneider E, Josifova T. Risks and sequelae of
scleral perforation during peribulbar or retrobulbar anesthesia. J Cataract
Refract Surg. 2010;36(6):885–9.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Lee et al. BMC Ophthalmology  (2017) 17:249 Page 5 of 5
